News
Menstrual literacy still deficient among Spanish women- study
Testimonies suggest menstruation remains a cause of mockery or derogatory comments
Menstruation does not receive the necessary attention, a new Spanish study has found, despite bill guaranteeing paid menstrual leave.
More than half of the women surveyed in a study, carried out by a team from the Universitat Politècnica de València and the Consejo Superior de Investigaciones Científicas, claim to not have known how to manage their first period.
The study, published in the journal BMC Women’s Health, analysed the information received about menstruation, the desired information and the information that has the greatest impact on how menstruation is experienced, and found that menstrual education in Spain is still deficient.
“Menstruation continues to be treated as an uncomfortable subject that has to be hidden and what is hidden is not talked about, is not investigated, is not legislated and does not receive the necessary attention. And menstrual health requires this attention,” said Sara Sánchez López, a researcher at the INGENIO Institute, a joint centre of the UPV and the CSIC, and lead author of the study.
The study, conducted through an anonymous online questionnaire of more than 4,000 people, addressed issues such as education received about menstruation, emotions experienced during menarche, period care products, economic impact, and social impact, among others.
It found the four most common emotions reported during the first menstruation were embarrassment (23 per cent), worry (20 per cent), fear (16 per cent), and stress (15 per cent).
Additionally, it showed that 35 per cent of the women surveyed did not know much about what their periods were when they first started, with more than half not knowing enough about how to proceed.
“Unfortunately, only five per cent of the people surveyed remember having received this information at school,” Sánchez López noted.
The data indicated that despite all the social changes that have occurred in the last decades, the emotions experienced during first menstruation in Spain have not varied significantly from the 1950s to the early 2000s.
A number of testimonies collected in the study suggested menstruation remains a cause of mockery or derogatory comments.
Rocío Poveda Bautista, a researcher at INGENIO and co-author of the study, said: “The ambiguity of current legislation regarding the contents on menstruation leaves it up to the discretion of the centre or even the teacher how much time to devote to the subject and what contents to include. Often, it is merely named in its biological function as part of human reproduction.”
The study highlighted the need for reliable and accessible information on how to manage menstrual pain, symptoms of endometriosis and other similar disorders, concluding that more knowledge is needed about how the menstrual cycle affects the whole body and how it varies throughout life.
“This study is intended to serve as a guideline for the creation of efficient legislative and social measures,” said Santiago Moll López, from the department of applied mathematics at the Universitat Politècnica de València and co-author of the study.
“It is a call to action so that menstrual health education, which is still deficient today, is incorporated into the curriculum, to ensure that every schoolchild in Spain receives basic and reliable information on this topic.”
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Menopause3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur6 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Wellness4 weeks agoVerdane invest in Clue to accelerate the future of women’s health






